{"cluster": 36, "subcluster": 55, "abstract_summ": "Herein, we review and discuss key immunologic effects of direct interleukin-6 blockade, downstream nonselective Janus kinase inhibition, and selective Janus kinase 2 suppression to treat coronavirus disease 2019\u2013related cytokine release syndrome.In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response.In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30th, 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality.However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines \u201ccytokine storm\u201d leading to an acute respiratory distress syndrome.", "title_summ": "Cytokine and anti-cytokine interventionsCan Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugsCOVID-19 revisiting inflammatory pathways of arthritisCytokine storm intervention in the early stages of COVID-19 pneumoniaCytokine Storm in COVID-19 patients transforms to a Cytokine Super Cyclone in patients with risk factorsLess Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferonsShould we stimulate or suppress immune responses in COVID-19?", "title_abstract_phrases": "We also overviewed antiviral immune response provided by BCG vaccine involving the IL-1\u03b2, IL-6 and TNF-\u03b1 secretion via \u2018trained monocytes\u2019, which confers early protection against SARS-CoV2.Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019Coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome-coronavirus-2 is a worldwide public health emergency that will have a lasting generational impact in terms of mortality and economic devastation.In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response.Herein, we review and discuss key immunologic effects of direct interleukin-6 blockade, downstream nonselective Janus kinase inhibition, and selective Janus kinase 2 suppression to treat coronavirus disease 2019\u2013related cytokine release syndrome.COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferonsThe outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into a major health hazard across the globe.Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30th, 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality."}